An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)

Trial Profile

An Open-label, Multicenter, Phase 2 Trial Investigating Sym004 in Patients With Metastatic Colorectal Cancer and Acquired Resistance to Anti-EGFR Monoclonal Antibodies and Documented Mutation of Extra Cellular Domain of EGFR (ECD-EGFR)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2017

At a glance

  • Drugs Futuximab/modotuximab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Symphogen
  • Most Recent Events

    • 17 Jan 2017 Status changed from recruiting to withdrawn prior to enrolment.
    • 06 Jan 2017 This trial was completed in Spain, according to European Clinical Trials Database.
    • 05 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top